HONG KONG, March 20, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study evaluates the global first-in-class PD-1/CTLA-4...
Hence then, the article about akeso s cadonilimab combined with concurrent chemoradiotherapy demonstrates promising efficacy in locally advanced cervical cancer data published at the 2025 sgo annual meeting was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting )
Also on site :
- Suspect in Mississippi synagogue fire laughed as he confessed to his dad, authorities say
- Fire crews and Hazmat teams responded to fire involving lithium ion batteries at Higuera Street facility
- No injuries reported after partial building collapse in the Bronx, officials say